Table 1.
Food and Drug Administration-approved ICB therapies
| Drug | Target | Histology | Key trials | Combination |
|---|---|---|---|---|
| Ipilimumab | CTLA-4 | Melanoma | NCT00094653 | Monotherapy |
| Nivolumab | PD-1 | Melanoma | Checkmate-037,069,067,238 | Ipilimumab |
| NSCLC | CheckMate-063, 017,057,227,9LA | Ipilimumab, Ipilimumab + platinum | ||
| RCC | CheckMate-025, 214 | Ipilimumab | ||
| Hodgkin’s lymphoma | CheckMate-205 | Monotherapy | ||
| Head and neck | CheckMate-141 | Monotherapy | ||
| Colorectal | CheckMate-142 | Ipilimumab | ||
| HCC | CheckMate-040 | Ipilimumab | ||
| SCLC | CheckMate-032 | Monotherapy | ||
| Bladder | CheckMate-275 | Monotherapy | ||
| Esophageal SCC | ATTRACTION-3 | Platinum, fluoropyrimidine | ||
| Pembrolizumab | PD-1 | Melanoma | KeyNote-001, 002,006,054/EORTC 1325 | Monotherapy |
| NSCLC | KeyNote-001,010, 024,021,189,407,042 | Pemetrex, cisplatin/carboplatin, paclitaxel | ||
| RCC | KeyNote-426 | Atixinib | ||
| Hodgkin’s lymphoma | KeyNote-087 | Monotherapy | ||
| Head and neck | KeyNote-012,048 | Platinum, fluorouracil | ||
| MCC | CITN-09/KeyNote-017 | Monotherapy | ||
| MSI-H | NCT01876511 | Monotherapy | ||
| Gastric | KeyNote-059 | Monotherapy | ||
| HCC | KeyNote-244 | Monotherapy | ||
| Cervical | KeyNote-158 | Monotherapy | ||
| PMBCL | KeyNote-170 | Monotherapy | ||
| SCLC | KeyNote-158,028 | Monotherapy | ||
| Bladder | KeyNote-045,052,057 | Monotherapy | ||
| Endometrial | KeyNote-146 | Lenvatinib | ||
| Cemiplimab | PD-1 | CSCC | NCT0276048 | Monotherapy |
| Avelumab | PD-L1 | RCC | JAVELIN Renal 101 | Axitinib |
| MCC | JAVELIN Merkel 200 | Monotherapy | ||
| Bladder | JAVELIN Solid Tumor | Monotherapy | ||
| Atezolizumab | PD-L1 | NSCLC | Birch, Poplar, FIR, Oak, IMpower150,130 ,110 | Bevacizumab, carboplatin, and paclitaxel |
| HCC | IMbrave150 | Bevacizumab | ||
| SCLC | IMpower133 | carboplatin, etoposide | ||
| Bladder | IMvigor210 | Monotherapy | ||
| Breast | IMpassion130 | n-ab paclitaxel | ||
| Durvalumab | PD-L1 | NSCLC | PACIFIC | Monotherapy |
| SCLC | CASPIAN | Carboplatin, etoposide | ||
| Bladder | NCT01693562 | Monotherapy |
CSCC, cutaneous squamous cell carcinoma; HCC, hepatocellular carcinoma; MCC, Merkel cell carcinoma; MSI-H, microsatellite instability- high; NSCLC, non-small cell lung cancer; PMBCL, primary mediastinal B-cell lymphoma; RCC, renal cell carcinoma; SCC, squamous cell carcinoma.
Information summarized from https://www.canceresearch.org/.